In this context, several studies have suggested to modernize the definition by incorporating key biomarkers of either placental or vascular origins, including placenta growth factor (PlGF) and antiangiogenic factors such as soluble fms-like tyrosine kinase-1 (sFLT1) or soluble endoglin (sENG) in the diagnosis of preeclampsia and the risk for developing the disease and even in predicting the outcome (Tjoa et al., 2007; Staff et al., 2013; March et al., 2015; Palomaki et al., 2015; Sircar et al., 2015; Baltajian et al., 2016). Here, ENG is linked to preeclampsia.